B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up

Non-small cell lung cancer (NSCLC) is still a big problem in oncology and unfortunately is the major responsible of cancer deaths worldwide (1). Increasing efforts have been made over the last two decades, allowing a more precise comprehension of the unique characteristics of this disease. The development of next-generation sequencing techniques has opened a new era of possibilities, owing to the identification of many mutations present in NSCLC, and the characterization of its genomic profile. The description of the epidermal growth factor receptor (EGFR) mutation, the demonstration of its involvement in carcinogenesis process and its posterior validation as a targetable mutation has established a new era of precision medicine and targeted-guided treatment in NSCLC following for the discovery of other druggable targets like ALK, ROS1 and recently c-MET among others (2-4).